Oligodendroglioma
Oligodendroglioma | |
---|---|
Micrograph of an oligodendroglioma showing the characteristic branching, small, chicken wire-like blood vessels and fried egg-like cells, with clear cytoplasm and well-defined cell borders. H&E stain. | |
Specialty | Neuro-oncology, neurosurgery |
Usual onset | Between ages 35 and 44[1] |
Prognosis | Five-year survival rate: 74.1%[1] |
Frequency | ~1,217 new diagnoses per year (United States)[1] |
Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the brain or from a glial precursor cell. They occur primarily in adults (9.4% of all primary brain and central nervous system tumors) but are also found in children (4% of all primary brain tumors).
Signs and symptoms
Oligodendroglioma arise mainly in the
Cause
The cause of oligodendrogliomas is unknown. Some studies have linked oligodendroglioma with a viral cause. A 2009 Oxford Neurosymposium study illustrated a 69% correlation between NJDS gene mutation and the tumor initiation.[citation needed] A single case report has linked oligodendroglioma to irradiation of pituitary adenoma.[4][5]
Diagnosis
Microscopic appearance
Oligodendrogliomas cannot currently be differentiated from other brain lesions solely by their clinical or radiographic appearance. As such, a brain
Classically they tend to have a vasculature of finely branching capillaries that may take on a "chicken wire" appearance. When invading grey matter structures such as cortex, the neoplastic oligodendrocytes tend to cluster around
Oligodendrogliomas must be differentiated from the more common astrocytoma. Non-classical variants and combined tumors of both oligodendroglioma and astrocytoma differentiation are seen, making this distinction controversial between different neuropathology groups. Molecular diagnostics may make this differentiation obsolete in the future. Although, in normal brain tissue, OLIG2 expresses on oligodendrocytes but not on mature astrocytes, it expresses similarly on both adult astrocytoma (including both IDH-mutant diffuse astrocytoma and anaplastic astrocytoma, as well as IDH-wildtype glioblastoma) and oligodendroglioma.[7] Therefore, OLIG2 should not be used to differentiate these classes of adult gliomas, although the expression level might predict the IDH mutation status in some clinical circumstances.[7]
Other
Histopathological grading
This section's factual accuracy may be compromised due to out-of-date information. The reason given is: Obsolete as of the 5th revision (2021). (January 2024) |
The histopathologic grading of oligodendrogliomas is controversial. Currently, the most commonly used grading schema is based on the year 2007 World Health Organization (WHO) guidelines. An updated classification is in progress.[8] Oligodendrogliomas are generally dichotomized into grade II (low grade) tumor.
Unfortunately, the WHO guidelines include subjective criteria in grade II. In addition, the presence of low mitotic activity, vascular proliferation and necrosis, including pseudopallisading necrosis, is insufficient by itself to elevate the grade of this tumor. This leads to inevitable interobserver variability in diagnosis by pathologists. The ultimate responsibility for making treatment decisions and interpretation of this diagnosis lies with the oncologist in consultation with the patient and their family.
It has been proposed that
The updated WHO guidelines published in 2007 recommends classifying such tumors for the time being as 'glioblastoma with oligodendroglioma component'.[9] It remains to be established whether or not these tumors carry a better prognosis than standard glioblastomas.
Molecular genetics
In WHO 2021 CNS5 Classification,[11] oligodendroglioma is named "Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted", and requires the presence of IDH1 or IDH2 mutations and the codeletion of chromosome 1p and 19q arms. Interestingly, oligodendroglioma has a higher rate of IDH2 mutation than astrocytoma,[7] so the IHC antibody against the common IDH1 p.R132H mutant[12] might not pick up the mutation.
By far, the most common structural deformity found is co-deletion of chromosomal arms 1p and 19q. The high frequency of co-deletion is a striking feature of this glial tumour and is considered as a "genetic signature" of oligodendroglioma.
Whereas the prognostic relevance of 1p and 19q deletions is well established for mixed oligoastrocytomas, the prognostic relevance of the deletions for low-grade gliomas is more controversial. In terms of low-grade gliomas, a recent study also suggests that 1p/19q co-deletion may be associated with a (1;19)(q10;p10) translocation which, like the combined 1p/19q deletion, is associated with superior overall survival and progression-free survival in low-grade glioma patients.[16] Oligodendrogliomas show only rarely mutations in the p53 gene, which is in contrast to other gliomas.[17] Epidermal growth factor receptor amplification and whole 1p/19q codeletion are mutually exclusive and predictive of completely different outcomes, with EGFR amplification predicting poor prognosis.[18] There is a strong correlation between 1p/19q codeletion and the expression of proneural genes, suggesting that gliomas with a 1p19q codeletion represent a subgroup of proneural gliomas.[18]
Treatment
Oligodendrogliomas are generally considered to be incurable using current treatments. However compared to the more common
However, such figures can be misleading since they do not factor in the types of treatment nor the genetic signature of the tumors. A recent study analyzed survival based on chromosomal deletions and the effects of radiation or chemotherapy as treatment, with the following results (both low-grade and anaplastic oligodendrogliomas): 1p/19q deletion with radiation = 121 months (mean), 1p/19q deletion with chemotherapy = over 160 months (mean not yet reached), no 1p/19q deletion with radiation = 58 months (mean), and no 1p/19q deletion with chemotherapy = 75 months (mean).[20]
Given the indolent nature of this tumor and the potential
The standard dosing schedule of temozolomide is five consecutive days of daily dosing during 28-day cycles. However, different dosing schedules may produce better results, such as continuous daily dosing using lower amounts of drug (e.g. 21-day dosing during 28-day cycles). As an example of an altered dosing schedule, promising results have been shown using lower daily doses on each day for 7 weeks, followed by a 4-week off periods.[21] Regarding the duration of dosing, for oligodendrogliomas the duration prescribed by oncologists varies considerably ranging from 6 cycles to over 32 cycles (i.e. over three years). In one study, researchers compared patients who received temozolomide for at least 12 months on the 5/28 day cycle, dividing such patients into two groups: "short term" patients receiving temozolomide for 12–18 cycles and those "long term" patients receiving 19 or more cycles (range was 19 to 32 cycles). Researchers found that there was a statistically significant advantage for "long term" treatment (median progression free survival for "short term" patients was 95 weeks (follow-up of 73 weeks), but for "long term" patients the median progression free survival was not yet reached (follow-up of 134 weeks)).[22][23]
Due to the diffusely infiltrating nature, oligodendrogliomas cannot be completely resected and are not curable by surgical excision. If the tumor mass compresses adjacent brain structures, neurosurgeons typically remove as much of the tumor as possible without damaging other critical, healthy brain structures. Surgery may be followed up by chemotherapy, radiation, or a mix of both, however recent studies suggest that radiation does not improve overall survival (even when age, clinical data, histological grading, and type of surgery are considered).[20][24][25]
Prognosis
Oligodendrogliomas, like all other infiltrating
Long-term survival is reported in a minority of patients.[26] With aggressive treatment and close monitoring, it is possible to outlive the typical life expectancies for low grade oligodendroglioma. Westergaard's study (1997) showed that patients younger than 20 years had a median survival of 17.5 years. For patients that are over 30, the survival rate is lower but as treatment options grow, the survival rate is higher. However, a patient with bad general health is more likely to die sooner than those that have good general health.[27] Another study shows a 34% survival rate after 20 years.[28] However, as discussed above, such figures can be misleading since they do not factor in the types of treatment nor the genetic signature of the tumors. Additionally, such historic data loses significance due to the relatively long survival of patients (compared to other types of brain tumors) and the introduction of newer treatment options over time.
References
- ^ a b c "Oligodendroglioma Diagnosis and Treatment". National Cancer Institute. 17 September 2018. Retrieved March 8, 2023.
- ^ a b "Oligodendroglioma". The Lecturio Medical Concept Library. Retrieved 21 August 2021.
- ^ Sandra G. Boodman (2023-02-18). "She thought anxiety and drinking made her ill. The truth was scarier". Washington Post. Retrieved 2023-03-01.
- PMID 3325615.
- ^ NEJM 867-5309, ed 6, p112–116, Kevin Smith etal
- ^ ISBN 9789283245087.
- ^ PMID 35856894.
- ^ http://www.reseau-pola.org/app/download/24869531/La+Lettre_RENOP_5.pdf [bare URL PDF]
- PMID 17618441.
- ^ PMID 33293629.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link
"This article is licensed under a Creative Commons Attribution 4.0 International License" - PMID 34185076.
- S2CID 208235398.
- ^ PMID 15709179.
- PMID 16292170.
- S2CID 39812093.
- PMID 17047046.
- PMID 1933879.
- ^ PMID 18492260.
- PMID 15977639.
- ^ S2CID 2416961.
- S2CID 15174867.
- .
- ^ Anderson K. and Lindsey W., "What is the optimal length of treatment with Temodar (temozolomide) for glioblastoma?", Online at http://virtualtrials.com/pdf/temodarlength.pdf
- ISSN 0732-183X.
- S2CID 27456056.
- S2CID 9844062.
- ^ Herbert H. Engelhard, M.D., Ph.D., Ana Stelea, M.D., and Arno Mundt, M.D., "Oligodendroglioma and Anaplastic Oligodendroglioma: Clinical Features, Treatment, and Prognosis", p. 449
- S2CID 31560940.
External links
- Brain and Spinal Tumors: Hope Through Research (National Institute of Neurological Disorders and Stroke)
- CT and MR Scans Classic Radiology Imaging of Oligodendroglioma
- http://www.reseau-pola.org/app/download/24869531/La+Lettre_RENOP_5.pdf